Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.
Not thousands of headlines. The few lines that move price. For traders: straight from the source, clear and simple.
Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.
Spending all your cash first can make your income surge in later years.
Elon Musk is set to reintroduce the Roadster sports car, possibly equipped with SpaceX thrusters.
It’s getting more expensive for investors to buy protection against a CoreWeave default.
The continued selloff in the AI trade is forcing investors to ditch highflying tech for relative safety of government bonds, even as hot inflation threatens to make that trade complicated.
The open-enrollment period goes from Oct. 15 to Dec. 7.
Reported details about Anthropic’s financial progress are adding to concerns about the health of the AI ecosystem.
The index may not move much because the stocks with the biggest weightings lag, but there’s a bull market starting to bubble elsewhere, says a hedge-fund manager.
Steven Jon Kaplan sees a completely irrational stock market right now, and investors ignoring a perfectly safe way to play that.
“I have some reservations about the long-term stability of my younger son’s marriage.”
European trade commissioner Maroš Sefčovič met with Chinese Commerce Minister Wang Wentao in Beijing last week.
Jake Johnson is looking to sell his four-bedroom, four-bathroom Southern California property, which offers approximately 3,153 square feet of living space.
Fewer shorts, buybacks ending, no inflows and too many longs imply no recovery is imminent, says a JPMorgan strategist.
The semiconductor foundry announced third-quarter net profits of 763.34 Taiwanese new dollars, marking a record.
Anthropic’s revenue growth appears to be cooling as the company prepares for its public debut, further stoking investors’ AI jitters
Investors are wondering if steep inflation and increased borrowing costs could derail the AI buildout.
Neutron, a medium-lift rocket meant to rival SpaceX’s Falcon 9, will no longer launch this year.
For most of U.S. history, an all-stock and a 60-40 portfolio have run neck-and-neck for trailing 30-year returns.
The CEO’s the U.S.’s biggest banks all chimed in on the risks of related to the massive AI buildout, but how there’s still no sign that investments need to slow down.
Buckle up: Small-cap stocks just hit a market milestone they’d rather avoid.
News text belongs to its source; only the headline and a short summary appear here.